Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Clin Cancer Res. 2014 Feb 28;20(9):2338–2349. doi: 10.1158/1078-0432.CCR-13-3157

Figure 1. Impact of Epstein-Barr virus (EBV) infection on overall and progression-free survival of patients with diffuse large B-cell lymphoma (DLBCL).

Figure 1

A and B. In the training set (n=500), overall survival (OS) and progression free survival (PFS) were not significantly different between EBV+ DLBCL and EBV− DLBCL (P=.189 and P=.687, respectively). C. Lack of difference in OS between EBV+ DLBCL and EBV− DLBCL was reproduced (P=.849) in the validation set (n=232). D. Combining the training set and validation set, OS was not significantly different between EBV+ DLBCL and EBV− DLBCL (P=.192). E and F. EBV positivity in DLBCL also failed to show any significant difference in cases of germinal center B-cell (GCB) versus activated B-cell (ABC) phenotype, OS (P=.650 and P=.290, respectively).